home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

DIA’s Annual Canadian Meeting: Evolutions in Risk Thinking

  March 27, 2012  
Ottawa Mariott, Ottawa, Canada
Nov 6 2012 7:00AM - Nov 7 2012 4:00PM

Rethinking and Redesigning Traditional Approaches during Changes in the Industry

Benefit-risk considerations are a central concept to the development, authorization and marketing of health products. As the industry undergoes a period of unprecedented change, traditional approaches to drug development are being re-designed. As our way of thinking about and managing risk also evolves, and as we seek to optimize patient outcomes and minimize risk, this meeting will explore the challenges that industry, regulators, policy makers and those involved in health product lifecycle face in understanding and defining acceptable levels of risk across disciplines and through the drug development and lifecycle management. This conference will challenge participants to explore how our thinking about benefit-risk management has and continues to evolve.

The DIA’s Annual Canadian Meeting: Evolutions in Risk Thinking features:
• Preconference tutorials
• Cross-functional sessions dedicated to the different areas of interest
• Networking opportunities (reception, interaction with regulators, cross-disciplinary networking)
• Question and answer sessions
• Case studies
• Presentation of best practices
• Table top exhibits

Benefits of DIA’s Annual Canadian Meeting: Evolutions in Risk Thinking:
• Leave with solutions for development strategy
• Meet colleagues from business partner functions to discuss new ideas
• Look at a particular operations topic from different angles
• Network with professional colleagues
• Interact with speakers from the industry and regulatory agencies
• Enhance awareness of scientific areas

Event Code:
Organized by: DIA
Invited Speakers:
Program Co-Chairs
Neerja Goyal
Director, Regulatory Strategy and Policy
GlaxoSmithKline, Inc Canada
Paul Litowitz
A/Senior Advisor, DGO
Therapeutic Products Directorate, HPFB
Health Canada
Program Committee
Sandra Alderdice
Unit Head
Office of Regulatory Affairs, BGTD
Health Canada
Karen Feltmate
Redstone Health Group, Inc.
Alice Hui
Regulatory Project Management Division, TPD
Health Canada
Chanez Kebache
Drug Safety Surveillance Specialist
Andrew Storey
Senior Vice President
Quality and Regulatory Affairs
Cangene Corporation
Deadline for Abstracts: April 23, 2012
Marilyn Ginsberg, Customer Service Associate
Phone +1.215.442.6135
Fax +1-215.442.6199
Email Marilyn.Ginsberg@diahome.org

Joanne Wallace, CMP, Program Manager
Phone +1.215.442.6180
Fax +1-215.442.6199
Email Joanne.Wallace@diahome.org


Attendees may visit the tabletop exhibits during the event and receptions
Contact Jeff Korn, Worldwide Exhibits Associate
Phone +1.215.442.6184
Fax +1.215.442.6199, 
Email Jeff.Korn@diahome.org

E-mail: joanne.wallace@diahome.org
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.